Champions Oncology Inc CSBR.OQ CSBR.O is expected to show a fall in quarterly revenue when it reports results on September 9 (estimated) for the period ending July 31 2025
The Hackensack New Jersey-based company is expected to report a 3.9% decrease in revenue to $13.513 million from $14.06 million a year ago, according to the estimate from one analyst, based on LSEG data.
LSEG's mean analyst estimate for Champions Oncology Inc is for a loss of 1 cent per share.
The one available analyst rating on the shares is "buy".
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Champions Oncology Inc is $12.00, about 42.4% above its last closing price of $6.92
This summary was machine generated September 5 at 11:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)